Top

Published in:

Open Access 01-06-2016 | Original Article

Disease-specific clinical trials networks: the example of cystic fibrosis

Authors: Kris De Boeck, Veerle Bulteel, Isabelle Fajac

Published in: European Journal of Pediatrics | Issue 6/2016

Abstract

This article describes the steps of the development and the structure of a disease-specific clinical trials network for cystic fibrosis in Europe. Activities such as reviewing study protocols, feasibility assessments, training and standardizing of procedures, and outcome measurements help to bring high-quality clinical trials to the patients. Cooperation with the pharmaceutical industry, other research networks, patient organizations, and regulatory agencies is very important throughout all activities.

Conclusion: The European Cystic Fibrosis Society—Clinical Trials Network facilitates the development of new treatments for a rare disease and could be a prototype for other diseases.

What is Known:

• Clinical research has led to the first approved treatments targeting the basic Cystic Fibrosis defect.

• For a rare disease like Cystic Fibrosis, multicenter international collaboration is needed to obtain solid evidence when testing possible new treatments.

What is New:

• The Clinical Trials Network established by the European Cystic Fibrosis Society has grown to a fully operational network with well-defined structures, procedures and partnerships.

• Standardization of outcome parameters, protocol review, feasibility assessment and other activities help to develop high quality, efficient, relevant and feasible clinical trials, with the aim to bring new treatments to the patients.

Bell SC, De Boeck K, Amaral MD (2015) New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 145C:19–34CrossRef

Boyle MP, De Boeck K (2013) A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 1(2):158–63CrossRefPubMed

Briggs TA, Bryant M, Smyth RL (2006) Controlled clinical trials in cystic fibrosis—are we doing better? J Cyst Fibros 5(1):3–8CrossRefPubMed

Carbone PP, Tormey DC (1991) Organizing multicenter trials: lessons from the cooperative oncology groups. Prev Med 20:162–169CrossRefPubMed

De Boeck K, Fajac I, Ratjen F (2014) End-points and biomarkers for clinical trials in cystic fibrosis. In: ERS monograph Cystic Fibrosis, European Respiratory Society., pp 104–115

De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe SM, Middleton P, De Jonge H, Bronsveld I, Wilschanski M, Melotti P, Danner-Boucher I, Boerner S, Fajac I, Southern K, De Nooijer RA, Bot A, De Rijke Y, De Wachter E, Leal T, Vermeulen F, Hug MJ, Rault G, Nguyen-Khoa T, Barreto C, Proesmans M, Sermet-Gaudelus I, on behalf of the European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee (2013) CFTR biomarkers: time for promotion to surrogate end-point? Eur Respir J 41:203–216CrossRefPubMed

De Boeck K, Tiddens H, Elborn S, Fajac I (2013) A new Clinical Trials Directive to boost academic trials? Lancet Respir Med 1(2):99–101CrossRefPubMed

Drazen JM (2015) Sharing individual patient data from clinical trials. N Engl J Med 372(3):201–2CrossRefPubMed

Fayon M, Kent L, Bui S, Dupont L, Sermet I, European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee (2014) Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis. Eur Respir J 43(2):610–26CrossRefPubMed

10.

Kent L, Reix P, Innes JA, Zielen S, Le Bourgeois M, Braggion C, Lever S, Arets HG, Brownlee K, Bradley JM, Bayfield K, O’Neill K, Savi D, Bilton D, Lindblad A, Davies JC, Sermet I, De Boeck K, European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) Standardisation Committee (2014) Lung clearance index: evidence for use in clinical trials in cystic fibrosis. J Cyst Fibros 13(2):123–38CrossRefPubMed

11.

Kerem E, Conway S, Elborn S, Heijerman H (2005) Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 4(1):7–26CrossRefPubMed

12.

Lebecque P, Leonard A, De Boeck K, De Baets F, Malfroot A, Casimir G, Desager K, Godding V, Leal T (2009) Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. J Cyst Fibros 8(1):26–30CrossRefPubMed

13.

McCormick J, Mehta G, Olesen HV, Viviani L, Macek M Jr, Mehta A (2010) Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 20(375):1007–13CrossRef

14.

Proesmans M, Vermeulen F, De Boeck K (2008) What’s new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur J Pediatr 167(8):839–49CrossRefPubMed

15.

Riordan J, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczack Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC (1989) Identification of the cystic fibrosis gene: cloning and characterization of the complementary DNA. Science 245:1066–1073CrossRefPubMed

16.

Smyth AR, Barbato A, Beydon N (2010) Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 35(2):247–65CrossRefPubMed

17.

Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73(7):1251–4CrossRefPubMed

18.

Zolin A, Van Rens J, Fox A, Iansa P, Preftitsi A, Pypops U, Gulmans V, Jung A, Mehta A, Viviani L, Vebert Olesen H, McKone EF (2014) ECFSPR Annual Report 2010

Title: Disease-specific clinical trials networks: the example of cystic fibrosis
Authors: Kris De Boeck
Veerle Bulteel
Isabelle Fajac
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 6/2016
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-016-2712-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Disease-specific clinical trials networks: the example of cystic fibrosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children’s hospitals

The effect of red blood cell transfusion on the microcirculation of anemic children

Asthma and atopic dermatitis in children born moderately and late preterm

Are adolescents with high self-esteem protected from psychosomatic symptomatology?

Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion

Skin conductance in neonates suffering from abstinence syndrome and unexposed newborns